Lecture 10: Familial Coronary Heart Disease
Introduction
Presenter: Cara Barnett, Genetic Counselor in Cardiology at Cincinnati Children's
No conflicts of interest to disclose.
Objectives
Identify different categories of heart disease.
Describe clinical aspects and risk factors for coronary artery disease (CAD).
Describe lipoproteins and lipid disorders.
Conduct risk assessment for familial hypercholesterolemia (FH).
Recognize additional lipid disorders.
Overview of Cardiovascular Disease
Leading cause of death across many demographic groups in the U.S.
In 2021, one in five deaths were attributed to heart disease, predominantly CAD.
CAD affects various age groups; one in 20 adults over 20 years have CAD.
Increasing incidences of heart attacks among younger populations.
Heart attacks occur approximately every 40 seconds in the U.S.
Types of Cardiovascular Disease
Includes ischemic and non-ischemic disease.
Atherosclerotic Cardiovascular Disease (ASCVD): Characterized by plaque buildup in arteries (fat, cholesterol, calcium).
Types include:
CAD
Cerebrovascular disease
Peripheral artery disease
Aortic diseases
Coronary Artery Disease (CAD)
Most common heart disease type in the U.S., accounting for one in seven deaths.
Ischemia: Insufficient blood flow to tissue; possible damage or death of heart muscle.
Heart requires oxygen-rich blood supplied by coronary arteries.
Myocardial infarction or heart attack is a significant outcome of ischemic injury.
Symptoms of Heart Attack
Primary symptom: Chest pain and discomfort, often described as spreading through the chest and upper abdomen.
Other symptoms:
Shortness of breath
Fatigue
Nausea/vomiting
Lightheadedness/fainting
Diagnosis and Treatment of Heart Attacks
Classification
ST Elevation Myocardial Infarction (STEMI): 100% blockage.
Non-ST Elevation Myocardial Infarction (Non-STEMI): Partial blockage.
Diagnostic Tests
Electrocardiogram (ECG) to identify damage and blockage.
Angiogram for blockage assessment.
Blood tests for tissue damage markers.
Treatment Options
Stenting: Insertion of a stent to relieve blockage.
Coronary Artery Bypass Grafting (CABG): Bypass surgery for damaged arteries.
Causes of Heart Attacks
Predominantly caused by dyslipidemia (abnormal lipid levels).
Hyperlipidemia: Excess fats in blood, prevalent in developed countries, leads to plaque formation.
Risk factors for CAD include:
Body composition
Hypertension
Smoking
Older age
Male sex
Diabetes
Understanding Lipids and Lipoproteins
Lipids: Fats including cholesterol and triglycerides, transported by lipoproteins.
Lipoproteins include:
LDL (Low-Density Lipoprotein): Bad cholesterol, high levels increase risk of heart attack and stroke.
HDL (High-Density Lipoprotein): Good cholesterol, protects against heart disease.
Triglycerides: Transported by chylomicrons and VLDL.
Routine lipid testing (lipid panels) measures total cholesterol, HDL, LDL, and triglycerides.
Normal Cholesterol Levels:
LDL: <160 (high if >160)
Total cholesterol: <240 (high if >240)
Triglycerides: <115 (normal)
Genetic Lipid Disorders
Lipoprotein A (Lp(a))
One in five people have high Lp(a); independent risk factor for ASCVD.
Elevated Lp(a) levels increase cardiovascular disease risk 2-4 fold for individuals with familial hypercholesterolemia.
Testing for Lp(a) is biochemical, normal level is <50.
Familial Hypercholesterolemia (FH)
A monogenic condition leading to high cholesterol from an early age.
Heterozygous FH prevalence: 1 in 250; homozygous FH: 1 in 300,000.
Significant elevation in total cholesterol (>300 in heterozygous). Premature coronary artery disease risk elevated 20-fold.
Suspect FH in:
LDL >160 for individuals under 20
LDL >190 for individuals over 20
250 indicates very high suspicion of FH.
Cholesterol Screening: Baseline recommended between ages 9-11, earlier for strong family history.
Genetic testing for FH recommended to diagnose and optimize treatment.
Clinical manifestations include early coronary artery disease and visible cholesterol deposits.
Clinical Models for FH Diagnosis
Models Include:
Dutch lipid model
U.S. MedPed model
Simon Broome model
Absence of clinical findings does not rule out FH.
Genetic Basis of FH
Caused by four main genes: LDLR, PCSK9, APOB, and LDLRAP1.
80% will show pathogenic variants when tested.
Genetic testing aids clinical management and treatment decisions.
Treatment of FH
Cholesterol lowering medications (statins) are primary treatment.
LDL Apheresis: Removes cholesterol from blood, addressed alongside lifestyle factors such as smoking cessation.
New therapies (PCSK9 inhibitors) shown to reduce LDL significantly.
Genetic testing aids in treatment justification and can enhance insurance coverage.
Other Types of Lipid Disorders
Familial Hyperchylomicronemia: Rare, caused by lipoprotein lipase deficiency; characterized by very high triglycerides.
Familial Dysbetalipoproteinemia: Common and underdiagnosed with skin manifestations (xanthomas).
APOB Mutations can cause both hyperlipidemia (dominant) and hypolipidemia (recessive), affecting fat absorption.
Conclusion
There are diverse lipid disorders, with familial hypercholesterolemia being the most common and significant.
Awareness of genetic risk factors and the role of genetic counseling is crucial for effective management and treatment.